Sobi’s VP and general manager for Spain and Portugal, Pablo De Mora, comments on his experience during the pandemic, the Swedish company’s haematology and immunology portfolio, including its EMA-approved COVID-19 treatment, and the reimbursement challenges faced by rare disease players in Spain. Moreover, De Mora highlights Sobi’s vast clinical trials operations in the country and how the organization is trying to “Humanize Rare Diseases.”
The Spanish ecosystem knows the recipe and understands that there must be a permanent dialogue between the administration, patients, HCPs, academia, regulatory authorities, and industry
